U.S. Capital Wealth Advisors LLC Buys 238 Shares of Zoetis Inc. (NYSE:ZTS)

U.S. Capital Wealth Advisors LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,331 shares of the company’s stock after purchasing an additional 238 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Zoetis were worth $1,520,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZTS. Pensionfund Sabic boosted its holdings in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new position in shares of Zoetis during the fourth quarter worth approximately $1,764,000. JPMorgan Chase & Co. lifted its holdings in shares of Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after purchasing an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in Zoetis in the 3rd quarter valued at $11,684,000. Finally, Nordea Investment Management AB increased its stake in Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.2 %

ZTS opened at $172.24 on Wednesday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company’s 50-day moving average price is $169.48 and its two-hundred day moving average price is $179.39. The stock has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.36 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.16%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.